Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia

Letizia Foroni, Gill Wilson, Gareth Gerrard, Joanne Mason, David Grimwade, Helen E White, David Gonzalez de Castro, Stephen Austin, Abida Awan, Emma Burt, Tim Clench, Joanna Farruggia, Jeremy Hancock, Alexandra E Irvine, Aytug Kizilors, Stephen Langabeer, Benedict J Milner, Guillermina Nickless, Anna Schuh, Anne SproulLihui Wang, Caroline Wickham, Nicholas C P Cross

Research output: Contribution to journalArticlepeer-review

87 Citations (Scopus)


Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the technique is most appropriate for patients who have achieved complete cytogenetic remission and can be used to define specific therapeutic milestones. To achieve this effectively, standardization of the laboratory procedures and the interpretation of results are essential. We present here consensus best practice guidelines for RT-qPCR testing, data interpretation and reporting that have been drawn up and agreed by a consortium of 21 testing laboratories in the United Kingdom and Ireland in accordance with the procedures of the UK Clinical Molecular Genetics Society.
Original languageEnglish
Pages (from-to)179-90
Number of pages12
JournalBritish Journal of Haematology
Issue number2
Early online date08 Mar 2011
Publication statusPublished - Apr 2011

Bibliographical note

© 2011 Blackwell Publishing Ltd.


  • Fusion Proteins, bcr-abl
  • Great Britain
  • Humans
  • Ireland
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Molecular Biology
  • Monitoring, Physiologic
  • Practice Guidelines as Topic
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • RNA, Neoplasm
  • Reverse Transcriptase Polymerase Chain Reaction
  • Societies, Medical

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia'. Together they form a unique fingerprint.

Cite this